SVB Wealth’s Protagonist Therapeutics PTGX Stock Holding History

SVB Wealth’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-261	Closed	-$12.6K	–	1337
2025 Q1	$12.6K	Buy	+261	New	+$10.9K	﹤0.01%	839

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SVB Wealth's PTGX Position: Q2 2025 in Review

SVB Wealth sold out of Protagonist Therapeutics (PTGX) in Q2 2025, closing a stake of 261 shares — an estimated $12.6K sold.

SVB Wealth first reported a position in PTGX in Q1 2025 and held it in 1 quarter. The position peaked at $12.6K in Q1 2025. 272 funds tracked by Wall St. Rank hold PTGX as of Q2 2025.

SVB Wealth reported no remaining Protagonist Therapeutics position as of Q2 2025 after selling out during the quarter.
SVB Wealth sold 261 Protagonist Therapeutics shares in Q2 2025, an estimated $12.6K.
SVB Wealth first reported a position in Protagonist Therapeutics in Q1 2025 and held it in 1 quarter.
SVB Wealth's Protagonist Therapeutics position peaked at $12.6K in Q1 2025.
272 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2025.

Based on SVB Wealth's 13F filing for Q2 2025, filed 14 Aug 2025.